|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/17 | |
| A61K 38/22 | |||
| A61K 47/68 | |||
| C07K 14/44 | |||
| C07K 14/195 | |||
| A61P 5/00 |
| (11) | Number of the document | 3411062 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17748111.6 |
| Date of filing the European patent application | 2017-02-02 | |
| (97) | Date of publication of the European application | 2018-12-12 |
| (45) | Date of publication and mention of the grant of the patent | 2020-11-25 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2017/016120 |
| Date | 2017-02-02 |
| (87) | Number | WO 2017/136492 |
| Date | 2017-08-10 |
| (30) | Number | Date | Country code |
| 201662290202 P | 2016-02-02 | US |
| (72) |
LIU, Yang, US
ZHENG, Pan, US
DEVENPORT, Martin, US
|
| (73) |
Oncoimmune Inc.,
9430 Key West Avenue Suite 113, Rockville, Maryland 20850,
US
|
| (54) | USE OF CD24 PROTEINS FOR TREATING LEPTIN-DEFICIENT CONDITIONS |
| USE OF CD24 PROTEINS FOR TREATING LEPTIN-DEFICIENT CONDITIONS |